Connect with us

Health

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Closes Enrollment In 12-Week Pivotal Study

Published

on

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) reported the dosing of patients and completion of enrollment in their pivotal single injection trial on the unmet medical need of grave osteoarthritis of the knee. These subjects witness pain and also the loss of function and poor quality of life. The main endpoint of this pivotal study follows the OARSI guidance, using the OMERACT-OARSI responder rate to resolve the symptoms and signs of severe OAK.

Michael Macaluso, the CEO, expressed that reporting the close of enrollment so quickly highlights the unmet medical need. They have seen Ampion™ to be both effective and safe in the clinical advancement of more than 1900 subjects, many of whom don’t have alternative treatment options.

The details

Ampio Pharmaceuticals considers that Ampion™ will be identified as a reference product upon FDA nod of their BLA. Reference offerings are allowed 12 years of exclusivity. Particularly, the FDA is not allowed to approve a filing for a biosimilar or interchangeable offering until 12 years following the date of the initial licensure of the reference offering.

The current Ampion™ portfolio holds patent coverage in all prime jurisdictions across the world, including the U.S., Europe, China, Eurasia, Hong Kong, Australia, Brazil, Canada, Japan, Korea, Mexico, India, Indonesia, Israel, Singapore, South Africa, Malaysia, New Zealand and Philippines, for pharmaceutical methods and compositions of curing a range of ailments. The portfolio comprises 85 pending applications and 125 issued patents throughout seven major patent families with expiration dates that spread to 2035.

Osteoarthritis is an ailment related to degradation of the intra-articular cartilage, bone, joint lining and ligaments. The incidence of suffering from OAK over a lifetime is nearly 45%. As this ailment is linked with diabetes, age and obesity, this count is expected to grow.

In the last trading session, the stock price of Ampio jumped more than 6% to close the day at $0.555.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement